Burning Rock Biotech (NASDAQ:BNR) Announces Quarterly Earnings Results

Burning Rock Biotech (NASDAQ:BNR) released its quarterly earnings data on Tuesday. The company reported ($1.08) EPS for the quarter, beating the consensus estimate of ($1.40) by $0.32, Zacks reports. The business had revenue of $17.27 million for the quarter. Burning Rock Biotech had a negative net margin of 83.50% and a negative return on equity of 60.68%.

Burning Rock Biotech Stock Performance

Shares of BNR opened at $4.75 on Thursday. The business’s 50-day moving average is $6.25 and its two-hundred day moving average is $5.28. The company has a market capitalization of $48.66 million, a P/E ratio of -1.58 and a beta of 0.55. Burning Rock Biotech has a fifty-two week low of $2.62 and a fifty-two week high of $8.99.

Burning Rock Biotech Company Profile

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.